Dashboard
Manage Tickers

IMVT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

immunovant-q2-eps-073-misses-072-estimate
Immunovant Q2 EPS $(0.73) Misses $(0.72) E...
11/10/2025 12:03:20

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.72) ...

mondaycom-metsera-profrac-holding-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Monday.Com, Metsera, Profrac Holding And O...
11/10/2025 11:18:29

earnings-scheduled-for-november-10-2025
Earnings Scheduled For November 10, 2025
11/10/2025 11:12:02

insights-into-immunovants-upcoming-earnings
Insights into Immunovant's Upcoming Earnings
11/07/2025 14:02:55

cardinal-health-posts-upbeat-q1-results-joins-guardant-health-glaukos-ch-robinson-and-other-big-stocks-moving-higher-on-thursday
Cardinal Health Posts Upbeat Q1 Results, J...
10/30/2025 14:19:43

watching-immunovant-shares-moving-higher-traders-circulate-unconfirmed-rumor-co-mentioned-by-ma-blog
Watching Immunovant; Shares Moving Higher,...
10/30/2025 14:06:03

truist-securities-initiates-coverage-on-immunovant-with-hold-rating-announces-price-target-of-16
Truist Securities Initiates Coverage On Im...
10/14/2025 13:11:00

Truist Securities analyst Danielle Brill initiates coverage on Immunovant (NASDAQ:IMVT) with a Hold rating and announces Pri...

jp-morgan-maintains-overweight-on-immunovant-lowers-price-target-to-33
JP Morgan Maintains Overweight on Immunova...
09/30/2025 12:29:23

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $37 to $33.

hc-wainwright--co-reiterates-buy-on-immunovant-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
09/04/2025 10:39:09

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $35 price target.

immunovant-reports-durability-and-treatment-free-6-month-remission-data-unveils-80-response-rate-in-off-treatment-graves-disease-study
Immunovant Reports Durability And Treatmen...
09/03/2025 17:00:43

First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the si...

jp-morgan-maintains-overweight-on-immunovant-lowers-price-target-to-37
JP Morgan Maintains Overweight on Immunova...
08/12/2025 15:44:49

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $40 to $37.

b-of-a-securities-maintains-buy-on-immunovant-lowers-price-target-to-30
B of A Securities Maintains Buy on Immunov...
08/12/2025 12:00:51

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $33 ...

immunovant-q1-eps-071-inline
Immunovant Q1 EPS $(0.71), Inline
08/11/2025 11:13:55

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 18....

ubs-maintains-neutral-on-immunovant-raises-price-target-to-18
UBS Maintains Neutral on Immunovant, Raise...
07/28/2025 22:18:14

UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $17 to $18.

immunovant-q4-eps-064-beats-073-estimate
Immunovant Q4 EPS $(0.64) Beats $(0.73) Es...
05/29/2025 11:09:30

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.73) by...

charles-schwab-to-rally-around-24-here-are-10-top-analyst-forecasts-for-tuesday
Charles Schwab To Rally Around 24%? Here A...
04/22/2025 13:37:04

ubs-downgrades-immunovant-to-neutral-lowers-price-target-to-17
UBS Downgrades Immunovant to Neutral, Lowe...
04/22/2025 11:58:38

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $38 to $17.

immunovant-appoints-eric-venker-currently-president-and-coo-of-roivant-as-ceo-tiago-girao-as-cfo-following-pete-salzmanns-retirement-as-ceo-and-director
Immunovant Appoints Eric Venker (Currently...
04/21/2025 11:25:28

guggenheim-reiterates-buy-on-immunovantto-buy
Guggenheim Reiterates Buy on Immunovantto Buy
03/20/2025 13:47:20

Guggenheim analyst Yatin Suneja reiterates Immunovant (NASDAQ:IMVT) from Buy to Buy.

b-of-a-securities-maintains-buy-on-immunovant-lowers-price-target-to-33
B of A Securities Maintains Buy on Immunov...
03/20/2025 10:32:24

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $38 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION